Please login to the form below

Not currently logged in
Email:
Password:

pimavanserin

This page shows the latest pimavanserin news and features for those working in and with pharma, biotech and healthcare.

Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

By a vote of 12 to 2, the advisory committee concluded that the benefits of Nuplazid (pimavanserin) outweigh its risks in PDP, setting up a possible FDA approval by the scheduled

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Srdjan Stankovic joins Acadia Pharmaceuticals Srdjan Stankovic joins Acadia Pharmaceuticals

    Nuplazid (pimavanserin), Acadia's lead candidate, has been submitted to the US FDA for a licence to treat Parkinson's disease psychosis, a condition that currently has no approved treatment.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics